We were unable to distinguish between type 1 and type 2 diabetes; we lacked clinical metrics (e.g., GFR) that might contraindicate the use of some medications; and some individuals may be receiving the medications for conditions other than diabetes. Glucagon-like-peptide-1 receptor agonists (GLP1as) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) offer advantages over older anti-diabetic agents, including increased survival among patients with comorbid cardiac or renal disease.[1], [2] Among privately insured adults, Black individuals are less likely to receive SGLT2is and GLP1as.[3], [4] However, about half of Black (and Hispanic) patients have public or no coverage. [Extracted from the article]